25th-28th January 2010Mediwatch UK Ltd STAND: 7C36
Product Categories: Urodynamic Systems ,Uroflowmetery ,Urology Consumables ,Urology Equipment
Mediwatch UK Ltd STAND: 7C36 Page 11
Wednesday, 27 January 2010
Arab Health 2010
Ah ha,I knew Mediwatch would be exibiting at this event,just took a while to find them.......
25th-28th January 2010
Mediwatch UK Ltd STAND: 7C36
Product Categories: Urodynamic Systems ,Uroflowmetery ,Urology Consumables ,Urology Equipment
Mediwatch UK Ltd STAND: 7C36 Page 11
25th-28th January 2010Mediwatch UK Ltd STAND: 7C36
Product Categories: Urodynamic Systems ,Uroflowmetery ,Urology Consumables ,Urology Equipment
Mediwatch UK Ltd STAND: 7C36 Page 11
Tuesday, 26 January 2010
Sunday, 24 January 2010
Future Events (Updated 2nd February)
A bit early but rather than go looking again I'll add any events I find here,ready for February's page:
43rd Annual Conference of Urological Society of India 3-7 February 2010
14th Annual Rodney Appell Memorial Update in Gynecologic Urology Conference 4-6 February 2010,The Westin Resort St.John, USVI (Mediwatch attended last year)
21st Annual International Colorectal Disease Symposium 11-13 February 2010,Florida (Mediwatch USA get a mention under "Exhibits,Grants and Donations"NOW CONFIRMED,MEDIWATCH ATTENDING/EXHIBITING
2010 Winter Meeting
February 23 – 27, 2010
SUFA 2010 Winter Meeting(Mediwatch are exhibiting)
43rd Annual Conference of Urological Society of India 3-7 February 2010
14th Annual Rodney Appell Memorial Update in Gynecologic Urology Conference 4-6 February 2010,The Westin Resort St.John, USVI (Mediwatch attended last year)
21st Annual International Colorectal Disease Symposium 11-13 February 2010,Florida (Mediwatch USA get a mention under "Exhibits,Grants and Donations"NOW CONFIRMED,MEDIWATCH ATTENDING/EXHIBITING
2010 Winter Meeting
February 23 – 27, 2010
SUFA 2010 Winter Meeting(Mediwatch are exhibiting)
Sunday, 17 January 2010
Mediwatch-Service Training Course Schedule 2010
Mediwatch is committed to providing the best training possible for the Distributors and Customers.
During 2010 Mediwatch will be running service support courses upon request at their UK base in Rugby.
Courses are conducted by their very experienced service staff who have unique detailed knowledge of the systems.
Should you have a specific request for service training from your engineers then please contact us at Mediwatch, and we will do our best to accommodate you.
Service Course Information
Duet & Sensic Family of Urodynamic Systems.
Urodyn 1000, Portaflow, Multiscan and Portascan+.
New additions: Portaflow Advanced.
Product Information: Bioscan.
Later this year: Urodyn+
This two day training course is designed to provide information to service engineers allowing them effectively to repair the Mediwatch range of Urodynamics and Ultrasound equipment up to board level.
Knowledge will be gained regarding servicing and calibration of the Duet and Sensic Family of systems, hardware identification, configuration and basic software operation.
The courses includes hands on operation and repair/troubleshooting of Duet, Urodyn 1000 and Ultrasound systems to basic board level, enabling the service and support staff to provide the best service for their customers.
The course is designed primarily for service engineers who are responsible for the repair and configuration of the Mediwatch range of products and who have little or no previous experience with these systems.
(Course content may be subject to change as new products are introduced.)
Mediwatch-Service Training Course Schedule 2010
During 2010 Mediwatch will be running service support courses upon request at their UK base in Rugby.
Courses are conducted by their very experienced service staff who have unique detailed knowledge of the systems.
Should you have a specific request for service training from your engineers then please contact us at Mediwatch, and we will do our best to accommodate you.
Service Course Information
Duet & Sensic Family of Urodynamic Systems.
Urodyn 1000, Portaflow, Multiscan and Portascan+.
New additions: Portaflow Advanced.
Product Information: Bioscan.
Later this year: Urodyn+
This two day training course is designed to provide information to service engineers allowing them effectively to repair the Mediwatch range of Urodynamics and Ultrasound equipment up to board level.
Knowledge will be gained regarding servicing and calibration of the Duet and Sensic Family of systems, hardware identification, configuration and basic software operation.
The courses includes hands on operation and repair/troubleshooting of Duet, Urodyn 1000 and Ultrasound systems to basic board level, enabling the service and support staff to provide the best service for their customers.
The course is designed primarily for service engineers who are responsible for the repair and configuration of the Mediwatch range of products and who have little or no previous experience with these systems.
(Course content may be subject to change as new products are introduced.)
Mediwatch-Service Training Course Schedule 2010
Just a reminder!
Just a reminder that there is quite a lot of information regarding Mediwatch PLC under the month of April 2009 which I'm hoping to update/tidy-up over the next few weeks.
For example:
General,Urology and Charity Websites
The Mediwatch Range
Distributors of Mediwatch Products
PSAwatch In Action
For example:
General,Urology and Charity Websites
The Mediwatch Range
Distributors of Mediwatch Products
PSAwatch In Action
Tuesday, 12 January 2010
Monday, 11 January 2010
“False positive” data from the European screening trial and other matters
This article is again nicked from The "New" Prostate Cancer InfoLink so I hope they don't mind.I've only copied part of their article but the link for the full text is below:
"The “game” of retrospectively analyzing every possible piece of data from the European Randomized Screening Study for Prostate Cancer (ERSPC) has been under way for a while now … and we can expect this game to produce lots and lots of controversial information and media coverage. But much of the data from these subset analyses will need to be treated with great caution.
Let’s look at just two current examples.
A new analysis of data from the Finnish section of the trial (where the men received a PSA test once every 4 years) has claimed that for every eight Finnish men who met the criteria for a biopsy, one man had a “false positive” result. But if you read even the abstract of the actual paper, you wonder whether this is really what the authors meant to state."
"The researchers defined a false positive result as “a positive screening result without cancer in [biopsy cores taken] within 1 year from the screening test.” But why on Earth would one define this as a “false positive” result? It is well understood that PSA levels rise for all sorts of reasons. It is perhaps shocking that as many as 7 men in 8 out of all those biopsied in Finland in this trial would have had a positive biopsy result! It is the biopsy that defines a diagnosis of cancer, not the PSA test. The PSA test only indicates the possibility of the cancer!"
“False positive” data from the European screening trial and other matters
"The “game” of retrospectively analyzing every possible piece of data from the European Randomized Screening Study for Prostate Cancer (ERSPC) has been under way for a while now … and we can expect this game to produce lots and lots of controversial information and media coverage. But much of the data from these subset analyses will need to be treated with great caution.
Let’s look at just two current examples.
A new analysis of data from the Finnish section of the trial (where the men received a PSA test once every 4 years) has claimed that for every eight Finnish men who met the criteria for a biopsy, one man had a “false positive” result. But if you read even the abstract of the actual paper, you wonder whether this is really what the authors meant to state."
"The researchers defined a false positive result as “a positive screening result without cancer in [biopsy cores taken] within 1 year from the screening test.” But why on Earth would one define this as a “false positive” result? It is well understood that PSA levels rise for all sorts of reasons. It is perhaps shocking that as many as 7 men in 8 out of all those biopsied in Finland in this trial would have had a positive biopsy result! It is the biopsy that defines a diagnosis of cancer, not the PSA test. The PSA test only indicates the possibility of the cancer!"
“False positive” data from the European screening trial and other matters
NEWS-Week Ending 17th January (Updated-4 Posts)
Ways To Cut Cancer Deaths In Europe Highlighted By New Study Europe-16th January
'False positive' concern over prostate cancer test BBC-11th January (worth reading in conjunction with "“False positive” data from the European screening trial and other matters" in above post)
Andrew Lloyd Webber gets cancer 'all clear' UK-11th January
Love Never Dies...but here's how I nearly did UK-10th January
'False positive' concern over prostate cancer test BBC-11th January (worth reading in conjunction with "“False positive” data from the European screening trial and other matters" in above post)
Andrew Lloyd Webber gets cancer 'all clear' UK-11th January
Love Never Dies...but here's how I nearly did UK-10th January
Saturday, 9 January 2010
New review of biomarkers for prostate cancer detection
This is taken from "The "New" Prostate Cancer InfoLink" website:
Nogueira et al. have just published a new “mini-review” in BJU International that addresses the potential roles of current and “future” biomarkers that may have relevance to prostate cancer detection. As ususal, this mini-review is available free to registered members of the UroToday web site, and offers a useful resource for prostate cancer support group leaders. (There appears to be a technical problem with the UroToday site at present. We will provide a direct link to this article as soon as possible.)
The article starts (and concludes) by noting that the PSA test (for all its problems) is still the current “gold standard” for the detection of potential risk for prostate cancer. However, the article focuses its attention on the capabilities of other biomarkers known to bear some relationship to prostate cancer risk, including:
•Human kallikrein 2 (hK2)
•Urokinase-type plasminogen activator receptor (uPAR)
•Prostate-specific membrane antigen (PSMA)
•Early prostate cancer antigen (EPCA)
•Prostate-specific antibodies
•Prostate cancer gene 3 messenger RNA (PCA3)
•Hypermethylation of the GTSP-1 gene
The authors suggest that all of the above markers continue to hold potential as methods to identify prostate cancer with greater specificity that the current PSA tests. However, their exact clinical utility is still not well defined at the present time, although the PCA3 test is commercially available in European countries and in the USA (although it has yet to be formally approved as a marker for the detection of prostate cancer in the USA).
New review of biomarkers for prostate cancer detection
Uro-Today website
Nogueira et al. have just published a new “mini-review” in BJU International that addresses the potential roles of current and “future” biomarkers that may have relevance to prostate cancer detection. As ususal, this mini-review is available free to registered members of the UroToday web site, and offers a useful resource for prostate cancer support group leaders. (There appears to be a technical problem with the UroToday site at present. We will provide a direct link to this article as soon as possible.)
The article starts (and concludes) by noting that the PSA test (for all its problems) is still the current “gold standard” for the detection of potential risk for prostate cancer. However, the article focuses its attention on the capabilities of other biomarkers known to bear some relationship to prostate cancer risk, including:
•Human kallikrein 2 (hK2)
•Urokinase-type plasminogen activator receptor (uPAR)
•Prostate-specific membrane antigen (PSMA)
•Early prostate cancer antigen (EPCA)
•Prostate-specific antibodies
•Prostate cancer gene 3 messenger RNA (PCA3)
•Hypermethylation of the GTSP-1 gene
The authors suggest that all of the above markers continue to hold potential as methods to identify prostate cancer with greater specificity that the current PSA tests. However, their exact clinical utility is still not well defined at the present time, although the PCA3 test is commercially available in European countries and in the USA (although it has yet to be formally approved as a marker for the detection of prostate cancer in the USA).
New review of biomarkers for prostate cancer detection
Uro-Today website
Wednesday, 6 January 2010
Urology Times-January 2010 Edition
As usual there are some interesting articles that relate to the field of health care Mediwatch cover:
Urology Times-January 2010 Edition
Urology Times-January 2010 Edition
Tuesday, 5 January 2010
FUTURE EVENTS AND LATEST NEWS(Updated 27th January)
Training Courses by or sponsored by Mediwatch
Fundamentals of Urodynamics Workshop Illinois-January 28-29
Future Events
The events listed below are of general interest and I will highlight any that Mediwatch are confirmed as attending/exhibiting at.
The 7th Meeting of the EAU Section of Oncological Urology (ESOU) Austria 15-17 January 2010-Mark Emberton (Mediwatch Non-Executive Medical Director) is contributing to this event.
Royal Society of Medicine Urology Section-Overseas Winter Meeting Austria 16-23 January 2010
57th Annual James C. Kimbrough Urological Seminar Texas 17-22 January 2010
Residents and Young Urologist in Urology-International Summit 2010 Turkey 23-24 January 2010
Arab Health 2010Dubai 25 to 28 January 2010
Mediwatch are exhibiting at the above event and can be found at Stand 7C36
20th International Prostate Cancer Update Colorado 27-30 January 2010
Mediwatch Newsletter (December 2009)
STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...
Mediwatch Interim Results for the six month ended 30 April 2009
Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009
Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009
Fundamentals of Urodynamics Workshop Illinois-January 28-29
Future Events
The events listed below are of general interest and I will highlight any that Mediwatch are confirmed as attending/exhibiting at.
The 7th Meeting of the EAU Section of Oncological Urology (ESOU) Austria 15-17 January 2010-Mark Emberton (Mediwatch Non-Executive Medical Director) is contributing to this event. Royal Society of Medicine Urology Section-Overseas Winter Meeting Austria 16-23 January 2010 57th Annual James C. Kimbrough Urological Seminar Texas 17-22 January 2010 Residents and Young Urologist in Urology-International Summit 2010 Turkey 23-24 January 2010 Arab Health 2010Dubai 25 to 28 January 2010Mediwatch are exhibiting at the above event and can be found at Stand 7C36
20th International Prostate Cancer Update Colorado 27-30 January 2010
Mediwatch Newsletter (December 2009)
STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...
Mediwatch Interim Results for the six month ended 30 April 2009
Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009
Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009
Saturday, 2 January 2010
Japan-MC Medical Website Update
MC Medical who are distributors for Mediwatch products have updated their website since I last looked (couple of months ago or more).They only listed two products before and now are showing four:
MC Medical
MC Medical
Subscribe to:
Comments (Atom)